Embed Size (px)
Citation preview
Deallus Consulting Ltd ● 1st Floor (South) ● 1 Swan Lane ● London ● EC4R 3TN ● United Kingdom t.
+44 (0)207 337 6900 ● f. +44 (0) 207 3376939 ● Website www.deallusconsulting.com Registered Office ● 1st Floor South ● 1 Swan Lane ● London ● EC4R 3TN ● Co Reg No: 05253532
Deallus Consulting-Internship Opportunity
The Company
There is an exciting opportunity for a Post Doc student at KI to get practical industry experience in Deallus Consulting, a Life Science competitive strategy consultancy. As a company, Deallus provides decision support to the pharmaceutical and biotech industry throughout their drug development and commercialisation process and we are currently looking for a smart, dynamic and enthusiastic individual to join us for a 2 month internship.
The Internship
As an Intern at Deallus you will be working as a team member with Associates and Consultants on a range of projects, supporting on activities from research through to proposal writing, giving you a strong exposure to the day-to-day running of a life science Consultancy. As an integral part of the team, we will help you develop valuable professional skills and you will participate fully on a range of projects, including, where possible, client interaction. Personable and enthusiastic, your can do attitude will push you to go the extra mile. The purpose of the internship is for those wanting a career in Life Sciences Consultancy and can be used as a stepping stone into a permanent role within the business. The learning curve will be steep and often challenging and you will get the support you need from a focused and dynamic team, but the professional rewards will be highly significant. We will provide training at the onset of your position to ensure that you can capitalise as best as possible on your time within our organisation. Internship duration: We would be looking for someone to start mid –late October and it will be for a fixed 2 months. The successful candidate will need to be able to work onsite from our London based office for the duration of their internship. Desired Skills & Experience Essential: - Postgraduate degree in the bio-medical or life sciences
- Strong Microsoft office skills including Word, Powerpoint and Excel
- Highly effective communicator, confident and assertive when necessary
- Interest in business and/or commercial acumen
- Strategic problem solving skills
- Quick learner and a strong sense of initiative
- Proven written and oral communication and presentation skills
- Driven, completer-finisher
- Strong team player Desirable: - Good knowledge of and application of pharmaceutical research resources
- Pharmaceutical or biopharmaceutical marketing or market research experience
- Strategy consulting experience
- Understanding of market/financial analysis in context of Life Sciences business needs
Deallus Consulting Ltd ● 1st Floor (South) ● 1 Swan Lane ● London ● EC4R 3TN ● United Kingdom t.
+44 (0)207 337 6900 ● f. +44 (0) 207 3376939 ● Website www.deallusconsulting.com Registered Office ● 1st Floor South ● 1 Swan Lane ● London ● EC4R 3TN ● Co Reg No: 05253532
The Learnings
Business Acumen Building on your academic knowledge, the internship will provide you with a unique perspective into the inner workings of the Life Sciences industry by providing you with a quickness and keenness in understanding and dealing with a business situation in a manner that is likely to lead to a good outcome. During your internship you will be exposed to the different stages of commercialisation and product development, different therapy areas beyond your PhD and how Pharma companies operate. Project Experience You will be a key contributor and team member on the projects to which you are assigned. You will be integral in the research aspect of the project and will be asked to contribute to the outputs and client insights. You will also grow your research skills in both Primary and Secondary research. Client Exposure There is the opportunity for you to become an integral part of the project team and to become involved in client meetings from an early stage.
The Process To learn more about this opportunity please contact us on [email protected] and [email protected]. To apply, please send your CV and cover letter to [email protected]. You will need to be able to work in the UK and hold the relevant passport or visa to do so. Please also highlight any conflict of interest limitations from previous employers. Please also include the web address of your Linked In profile if applicable. In your cover letter please look to include the reason why this opportunity appeals to you and the skills that you already have that would make you a successful candidate for this role. Interviewing for successful candidates will start immediately with an initial telephone interview followed by a case study interview.
Title: KI Researcher Internship at R&D, Bactiguard AB
Title: R&D literature searches
Gunilla Rydja Date: Page: Linda Bergström 2016-09-26 1(1)
Bactiguard The company Bactiguard has the vision of becoming a leader in reducing device related hospital acquired infections (HAIs). Through innovative technology and techniques, Bactiguard is providing a clinically proven, practical and cost effective solution. The proof of the Bactiguard® coating involves over 100,000 patients in clinical studies and over 150 million end users. The unique physical and chemical properties of the Bactiguard coating make it applicable on any medical device. The key ingredients in the Bactiguard coating are palladium, gold and silver. The Bactiguard® coating is unique and innovative in the sense that it combines antimicrobial and biocompatible properties in a way that makes it ideal for preventing device related infections without causing unwanted side-effects. Bactiguard currently have products from three therapeutic areas on the market:
• BIP Foley Catheter and BIP Foley Catheter – Silicone. Urinary tract catheters for drainage of urine.
• BIP ETT and BIP ETT Evac. Endotracheal tubes for respiratory aid during anesthesia. • BIP CVC, Central Venous Catheter. Venous access catheter for administrating drugs and
sampling of blood. For more information regarding the company and the products, visit: www.bactiguard.se The research internship project The internship will be divided into two literature search projects suitable for 1 candidate: One project (supervised by Gunilla Rydja, Director of Product Development and Market Access) will focus on mapping Guidelines for the different product areas that Bactiguard have on the market, including competitor analysis. This information is needed for better understanding of differences in clinical routines between countries and will be used for product development and in market material. The other project (supervised by Linda Bergström, Manager Microbiology) focuses on a couple of literature reports regarding Minimal Inhibitory Concentrations (MIC) and MSC (Minimal Selective Concentrations) for the noble metals of the Bactiguard coating, as well as a report on silver resistance. This information is needed in for example, safety evaluations of the products, and in market material. The projects are expected to give a benefit for the researcher by introducing him/her to the ISO quality systems and documentation mandatory for a Medical Device company. The researcher will gain a deeper understanding in systematically finding relevant information and to compile that according to ISO. (The project will not contain any lab work). The benefit for Bactiguard is to get help with gathering information and have it summarized in reports that will be frequently used and referred to. The Candidate The optimal candidate has a PhD in biological science, and experience in finding information/ performing literature searches and scientific writing in English.
Contact information: Gunilla Rydja, Director Product Development and Market Access, [email protected], direct: 08 440 98 65, mobile: 070 48 68 918 Linda Bergström, Manager Microbiology, [email protected], direct: 08 440 58 79, mobile: 076 006 30 09
Gnosco was founded in 2014 and believes in a mission to redefine the health care industry and improve processes to ensure faster and more qualitative care for patients, to utilize resources more efficient AND improve patient experience. Gnosco offers services and products for internal communication, documentation and continuous education within health care and hospitals called Dermicus. Dermicus is a complete platform for several areas and include mobile application, server, smartphone and dermatoscope. Dermicus improve internal communication, documentation and education within health care and hospitals. The Dermicus platform has delivered more than 7 000 consultations and maintains more than 32 000 images. Dermicus Mole is a telemedicine platform for early diagnosis and management of melanoma. Dermicus Wound is being developed in collaboration with Karolinska University Hospital and is financed within the frames of the Vinnova program Medtech4Health. Dermicus Wound aims to increase knowledge about diagnosis and treatment of chronic leg ulcers and in addition to stimulate the multidisciplinary collaboration between doctors, nurses and other health care professionals. Gnosco is looking for a talented intern to join our team in Stockholm or Gothenburg. As an intern at Gnosco you will get a chance to meet inspiring people and be part of a real entrepreneurial team. It is a great chance to learn and get hands-‐on experiences how you build a start-‐up in one of the most hyped and important area, global digital health. Project description: Multidisciplinary collaboration to manage chronic wounds by a new working method and a telemedicine platform The proportion of individuals over 65 years of age is increasing in Sweden, and estimated to make up 1/4 of the population in 2030. Chronic wounds primarily affects elderly, and are thus predicted to increase. Chronic wounds commonly include pain, reduced ability to move, isolation and a need for regular care, all of which may lower the quality of life of the individual. SBU reported in 2014, that there a lack of knowledge in the health care system regarding education, communication, and continuity within the field of chronic wounds. This may result in prolonged wound healing causing harm to the patient and unnecessary use of antibiotics. Dermicus Wound aims to support time cutting processes generating correct diagnosis and treatment of chronic wounds, while also being a platform for specialist competence, multidisciplinary communication and continuous education. Increased knowledge of leg ulcers and its causes will generate correct treatment early on with faster and improved chances of wound healing and in addition reduced use of antibiotics. Examples of activities the internship may involve: -‐ Contribute to the development of Dermicus Wound -‐ Collection of detailed specification requirements of the prototype -‐ Design documents for extracting data on patients with chronic leg ulcers -‐ Describe patient flow and organize the multidisciplinary work on the digital platform -‐ Perform quality, safety, and risk analysis of the product Dermicus Wound -‐ Design user questionnaires
-‐ Design patient questionnaires -‐ Define parameters to be measured during the performance phase -‐ Contribute to design of introductory education about chronic leg ulcers and Dermicus Wound -‐ Data collection from users of Dermicus Wound Personal skills and experience
• You are able to work on your own, take initiatives and have a strong personal drive. • An interest in digital health and med-‐tech is expected as well as an entrepreneurial spirit. • Gnosco values experience in project management, good analytical skills and social
competence. • To suit this position you have strong communication skills and are not afraid to pick up the
phone and call whomever. Contact Daniel Eliasson, CEO Email: [email protected] Phone: +46 (0)760 405012
an easy way to stay healthy for everyone!
Description
HealthiHabits is a health transformer dedicated to improving the life of individuals with a chronic
disease. Our unique patient-to-patient analytics platform empowers people to achieve a sustainable
lifestyle through instant and personalized support. This helps them to make better decisions in their
daily activities and gain control of their medical condition. Through innovative technology, we are
becoming a valuable partner to key players in the health care system. We are an ambitious startup in
digital health and committed to a bold vision: to connect everyone to the world’s healthiest
behaviors and create the easiest way to be healthy.
Project Description
HealthiHabits offers the opportunity of a 2 month fulltime postdoctoral internship (or as agreed,
part time). The incumbent will work on the product and technology development, customer and
market analysis, community building as well as broader topics. This may include (but is not limited
to) to specify the effectiveness of digital technology and interventions on medical conditions that
can be managed by sustainable behaviour and lifestyle changes. Scaled against the incumbent’s
background and interest, we offer the opportunity to be involved in and contribute to core aspects
of this venture. You will be working with a dynamic, international and highly experienced team in a
vibrant startup environment. Due to the nature of this project, we follow an agile methodology, and
certain aspects of our project become more important than currently anticipated, and may influence
this project’s focus.
Candidate’s Profile
Postdoctoral background in understanding chronic and lifestyle related diseases and have a
background, or an interest in developing skills around digital health, such as data science and social
technology, as well as expanding his/her network outside the university environment. We are
looking for self starters that are keen to move our vision forward.
Contact Details
The mentor of this project is Christian Guttmann (PhD). He is an entrepreneurially driven technology
leader with strong research and communication skills. His focus is on creating value in Digital Health
Care. At BT, IBM, HP and successful startups, he led innovation teams/projects using analytics and
AI, and social/mobile/IoT technology in health care. He creates high-impact systems, patents, and
scientific publications. He enjoys working with great teams and in productive partnerships. He has a
PhD in Artificial Intelligence, is an Adjunct at Karolinska, and an Adj. Associate Professor at UNSW.
Christian Guttmann, Founder, [email protected], 0707419945
Start
Flexible: until end 2016.
0
• Project Work Opportunity
This is an opportunity for student/researcher at KI to get practical industry experience within
the growing and highly important field of Real World Evidence and big data. IMS Health, a
world leading Consultancy Company within the Real World Evidence, Health Economics
and Outcome Research fields, wants to engage with young, smart and driven academics as
a way to collaborate with and to find the most talented people for the future.
• Project Description
In this project the overall objective is to perform practical Real World Evidence work and
epidemiological research with data from healthcare registries and electronic medical
records. You will get the opportunity to contribute to several projects that are in different
phases, you will perform desk research, preparations for data extractions,
analytical/statistical work, and/or science writing tasks such as study protocols, statistical
analysis plans, study reports, and scientific publications.
• Details on the Project
Depending on the background of the applicant and status of the ongoing research activities,
the work can be focusing on either of the following tasks:
1. Preparing for research projects involving the following activities
Desk research to gather evidence and literature required for protocol writing, ethical applications,
study design, etc
Drafting of study protocol
Preparation of ethical application
IMS Health_Project Description for Internship
Project Work Opportunity
IMS Health
1
2. Data extraction and analysis
Preparation of registry data applications
Field work activities related to the extraction of data from electronic medical records
Data management (cleaning, categorization of free text information, etc)
Drafting of statistical analysis plan
Participating in statistical analysis of registry based data
3. Dissemination
Drafting of clinical study report
Preparation for scientific publications (literature search, drafting texts, etc)
Contributing to dissemination material (abstracts, posters, etc)
The applicant will get the chance to take an active role in different phases of ongoing
research projects, typically large, retrospective, studies involving datasets gathered from
national registries, disease databases, hospitals, primary care units, etc within the fields of
oncology, infectious disease, respiratory disease, cardiovascular disease, etc. There are
opportunities to perform activities tailored to prior experience and know-how as well as to
learn new things and broaden the therapeutic knowledge.
In the end of the project you will get the opportunity to present and discuss the project work
with a broader Real World Evidence team in the Nordics.
• Contact Persons at IMS Health Sr Consultant, RWES: Julia Rockberg, PhD, E-mail: [email protected]
Human Resources: Simona Staaff-Lindgren, E-mail: [email protected]
IMS Health_Project Description for Internship
Project Work Opportunity
IMS Health
Internship at Omega Pharma Nordic AB (former ACO Hud Nordic AB)
Omega Pharma is the Branded Consumer Healthcare Division of Perrigo, a worldwide top 5 player in the OTC industry. In Europe, we have operations in 35 countries and a portfolio of more than 2.000 brands. Our clear vision is to be the most dynamic, successful and consumer-driven OTC Company in Europe. Our wide range of products includes both cosmetics and health solutions (medicines and lifestyle products). Innovation is the key driving force for future growth and forms a vital part in Omega Pharma's strategy.
In the Innovation group at Omega Pharma Nordic we develop new and innovative products for medicated skin care and we strive to make life easier for patients suffering from skin diseases such as eczema and psoriasis. The products we develop can have different regulatory status, i.e. cosmetics, medical devices or pharmaceuticals. To valorize our heritage of research and of publically sharing the results we aim to publish a review article of the current knowledge within the dry skin area. In the Kista office we have in- house product development and a wet laboratory. The applicant will work together with the Innovation team and will also get the opportunity to get introduced to other areas of the company.
We are looking for someone who is interested in working with the team both theoretically and practically. The work will include literature searches, compiling and summarizing the material and writing a scientific manuscript preferably ready for publication. There may also be opportunity to take part in laboratory work.
The applicant should speak and write English fluently and be an enthusiastic and independent writer. Knowledge in Physiology, Pharmacy or Physical Chemistry is meriting. However, the most important thing is that the applicant is thorough, curious, willing to learn new things and have the capacity to process large quantities of literature and to extract the relevant information. Contact information:
Tina Holm, PhD
Medical Officer
Omega Pharma Nordic
Tel: 073 274 41 13
www.omega-pharma.se
Anders Malarstig Director, Pfizer Worldwide Research & Development Vetenskapsvägen 10 191 92 Stockholm Tel: +46(8)55052514 [email protected]
Internship for Identification of Targets and Biomarkers in Liver Disease At Pfizer, we apply science and our global resources to improve health and well-being at
every stage of life. We strive to set the standard for quality, safety and value in the
discovery, development and manufacturing of medicines for people. Our global human
health care portfolio includes biologic and small molecule medicines and vaccines, and
many of the world's best-known consumer products. Pfizer has a major effort directed
towards the development of therapeutics for the following disease areas: Cardiovascular,
Endocrine and Metabolic Diseases, Neurosciences and Inflammatory Disorders.
Pfizer WRD is now offering an exciting internship opportunity that involves working in an
inter-disciplinary team that focuses on identifying new drug targets and biomarkers for non-
alcoholic fatty liver disease (NAFLD). The work includes reviewing and summarizing
important literature, internal presentations, review of planned or ongoing clinical trials in
NAFLD/NASH and statistical analyses of patient datasets. The analytical part of the
internship entails the analysis of liver biomarkers in a European study of 3,400 patients with
the metabolic syndrome. The intern will liaise with Pfizer colleagues based in Cambridge
Massachusetts as well as the local Pfizer team. We will provide the successful candidate
with experience from working in the research-based pharmaceutical industry and will ensure
that the candidate is allowed several opportunities for networking. We also hope to give
insights into strategic thinking, leadership and development opportunities in industry
research.
We expect the candidate to have experience with data analysis. We also require good
communication skills, especially written and spoken English. The project work will be carried
out partly at our premises in Silverdal, Sollentuna, and/or within our collaborator institution at
the Centre for Molecular Medicine at KI. There will occasionally be a need to take
teleconferences at inconvenient hours.
With best wishes, Anders Malarstig Human Genetics Director Pfizer Worldwide Research & Development [email protected]
Glycan mapping (GLM) of recombinant glycoproteins The Laboratory unit at the Medical Products Agency announces a short project aiming at
developing analytical method/s for control, analysis and characterization of glycosylated bio-
pharmaceuticals.
The Laboratory unit has 27 employees divided in three groups and the main responsibilities
are:
- Control and supervision of: licenced drug products, narcotics, unlicensed and
counterfeit drugs as well as cosmetics.
- Participates in the standardization of analytical methods (Pharmacopoeia
Monographs).
The candidate with supervisor will take an active role in the development of analytical
method for glycosylated bio-pharmaceuticals.
Background
Glycoprotein pharmaceutical are proteins containing oligosaccharides covalently attached to
the polypeptide chain. The carbohydrate is attached to the protein during the glycosylation
process, i.e., the post translation process. Glycosylation is important from the
pharmacokinetic-pharmacodynamic point of view. Glycosylation protect the protein against
N-deamidation, extend the half-life by protecting the protein against proteases as well as
affects the tertiary structure of the protein which in turn affects the affinity of the protein for
various receptors and ligands.
Glycan mapping is an important part of quality control of recombinant glycoproteins which is
performed by enzymatic cleavage of glycan moiety followed by fluorescence labelling and
analysis of the released glycans. Characterization and quantification of glycans are important
for assessment of biosimilarity. There are several analytical approaches which can be applied
to the glycan mapping, such as HPLC and CE coupled to fluorescence or amperometric
detectors as well as mass spectrometry.
This project aims at investigating new analytical procedures based on normal phase UPLC
coupled to fluorescence detector and mass spectrometry for the identification and
quantification of released glycans. Several glycoproteins, such as Ribonuclease B, IgG and
monoclonal antibodies are to be used as model glycoproteins. The released glycans are
labelled by a newly developed fluorophore tag prior to UPLC-FLR-MS analysis. The UPLC
column is modern column being used for separation of oligosaccharides.
For more information contact: Dr. Ahmad Amini ([email protected]) Dr. Martin Lavén ([email protected]) Tel: +4618-174600 Visiting address: Dag Hammarskjöldsväg 42 751 03 Uppsala
Internship project at Cepheid AB 2016 for a Post Doc / Researcher from Karolinska Institute
About Cepheid, GeneXpert Systems and Xpert Tests Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy‐to‐use molecular systems and tests. By automating highly complex and time‐consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic‐based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.
With more than 9,800 systems in 182 countries, the GeneXpert System is the world’s most popular molecular diagnostics’ instrument. The GeneXpert System’s modular configuration means that the system is the most scalable available, offering the ability to perform from one to eighty Xpert tests at the same time. As a result, the GeneXpert System meets the throughput requirements of customers of all sizes ‐ from lower volume point‐of‐care settings to higher volume reference laboratories. GeneXpert Systems run proprietary Xpert test cartridges. The Xpert test menu spans healthcare‐associated infections, sexual health, critical infectious disease, and oncology, and today offers 23 tests outside the US, and 19 tests in the US.
For more information, visit www.cepheid.com.
Latent TB Project More than 3 700 GeneXpert systems have been placed in 108 tuberculosis (TB) high‐burden countries, and more than 15 million Xpert MTB‐RIF tests have been shipped to date. As a complement to the Xpert MTB‐RIF test, a potential new test (Xpert Latent TB) should be able to identify persons with latent tuberculosis infection (LTBI), who do not have Active TB disease (i. e. not positive by Xpert MTB‐RIF or bacteria culture), but are latently infected and at risk of progression to disease. The WHO post‐2015 global TB strategy, which aims to reduce global TB incidence by 90% before 2035, encourages screening for LTBI in TB contacts and selected high‐risk groups with provision of appropriate prophylactic treatment for infected individuals.
Before development of an Xpert cartridge assay for LTBI testing can start, a target validation study is needed. Currently, candidate mRNA targets and normalizing markers are being evaluated on clinical blood samples from TB‐ and LTBI patients, as well as from normal healthy control donors. When an appropriate set of biomarkers has been identified based on RNA‐Seq and QPCR results, a multiplex PCR and prototype GeneXpert cartridge will be developed.
Internship Project 2016 This Internship Project will involve three parts;
(i) Assist in design of primers and probes for additional candidate target genes identified by RNA‐Seq, and evaluation of these designs on banked cDNAs from our ongoing target validation study. In this study, multiple cytokine‐ and IFN‐gamma induced chemokine candidate markers from M. tuberculosis‐recognizing T‐cells in immunostimulated whole blood have already been studied.
(ii) A literature study to summarize published information (marker performance and cohort characteristics) for our so far most promising candidate genes. The information is needed for a project review early 2017.
(iii) Depending on project progress during September‐November 2016, multiplex PCR and whole blood sample preparation optimization in a GeneXpert cartridge format. Cepheid use proprietary chemistry such as fluorescent dyes, quenchers and stabilizing bases in oligonucleotides.
Candidate Profile • Some knowledge in human genetics, familiar with SNP databases and preferably also with
basic design of primers and TaqMan probes for QPCR. • Some practical experience from PCR in expression analysis/diagnostics. • Period for this Internship Project is approx. from November 17, 2016 (possibly earlier).
Contacts Malin Nygren, PhD, Pre Concept Specialist, Research and Development Department of Research and Development, Cepheid AB, PO Box 1427, SE‐171 27 SOLNA, Sweden +46 8 6843 7145 [email protected] Per Grufman, PhD, Executive Director, Research and Development Department of Research and Development, Cepheid AB, PO Box 1427, SE‐171 27 SOLNA, Sweden +46 8 6843 7106 [email protected]
Postdoc secondment (2 months, fully financed KI) Project description Description of organisation The Swedish Research Council (SRC; Vetenskapsrådet) is the largest Swedish funding agency for basic research at Swedish universities, colleges and institutes. The SRC also functions as research policy advisor to the Government and works on the long-term expansion of knowledge within analysis, strategy and the monitoring of research and research funding. The SRC represents Sweden in numerous trans-national collaborations and joint calls between funding agencies in Europe and beyond. (see www.vr.se) Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is a trans-national collaboration between 20 countries to coordinate the research on antimicrobial resistance (AMR), in order to allow greater impact and avoid duplication. Sweden is the chair of JPIAMR and the SRC is hosting the secretariat of 5 persons (see www.jpiamr.eu) Description of project JPIAMR and VR will be setting up a database for reviewers based on expertise in AMR. This involves contacts with the EC, other users of reviewer databases, IT staff at VR, and programme officers at other funding agencies. The second part of the project involve analysis of AMR research and AMR funding. Results from the analysis will be used for the design and production of information material, web content and internal reports. The intern will also assist the secretariat on general JPIAMR tasks and communication via the website. Requested qualifications of applicant
Strong background in microbiology and/or infectious diseases is an advantage Knowledge of bibliometric analysis is an advantage Strong communication skills and web publishing skills is an advantage Fluency in English required whilst knowledge of Swedish is an advantage
Project period Start of project in the beginning of 2017 Contact person Patriq Fagerstedt, Senior Research Officer Unit for Science Policy Advice, Department of Science Policy, SRC 08-54644246, [email protected]
Datum Diarienummer
2016-09-27 Diarienummer Handläggare
Patriq Fagerstedt
1 (1)
1 (2)
Statens beredning för medicinsk och social utvärdering (www.sbu.se)
SBU ger kunskap för en bättre vård
Inom hälso- och sjukvården är personalen enligt lag skyldig att arbeta enligt vetenskap och beprövad erfarenhet. SBU, Statens beredning för medicinsk och social utvärdering, har i uppdrag att utvärdera metoder som används i vården och socialtjänsten. Utifrån aktuell och välgjord forskning tar vi reda på vilken effekt olika metoder har, om det finns några risker med dem, och om åtgärderna ger mesta möjliga nytta för pengarna. SBU:s oberoende utvärderingar ska användas som stöd av alla som på olika nivåer i samhället bestämmer hur hälso- och sjukvården ska se ut. Vi kan peka på möjligheter till ytterligare förbättring, så att sjukvården kan använda sina resurser på bästa sätt och Sveriges befolkning kan få en bättre hälsa.
SBU Kommenterar
Under de senaste femton åren har det skett en mycket kraftig tillväxt av publicerade utvärderingar (systematiska översikter). För att bättre utnyttja den kunskap som redan genererats av SBU-liknande organisationer i andra länder driver SBU sedan 2008 en ny verksamhet. Syftet är att sammanfatta utländska utvärderingar och analysera innehållet från ett svenskt perspektiv.
I korthet kan SBU Kommenterar beskrivas på följande sätt:
• Rapporterna är sammanfattningar med kommentarer till aktuella internationella kunskapsöversikter som har betydelse även för svensk hälso- och sjukvård och socialtjänst.
• SBU Kommenterar gör det lättare för beslutsfattare och personer som arbetar i vården att få tillgång till relevant internationell kunskap inom sitt område.
• Arbetet utförs av SBU:s kansli i samarbete med en utomstående expert på området. Kommentaren skrivs alltid tillsammans med en ämneskunnig person och innehåller ibland även en hälsoekonomisk analys.
• Rapporterna publiceras på www.sbu.se.
SBU Statens beredning för medicinsk och social utvärdering • www.sbu.se Telefon 08-412 32 00 • Fax 08-411 32 60 • Organisationsnummer 202100-4417 Besöksadress S:t Eriksgatan 117, Stockholm • Postadress Box 6183, 102 33 Stockholm
Projektbeskrivning
Vi söker en person som vill hjälpa oss att ta fram nya ”SBU Kommenterar” rapporter. Med handledning från SBUs personal innebär arbetet att sammanfatta en eller flera vetenskapliga översikter enligt en speciell arbetsprocess. Arbetet inbegriper att kritiskt granska samt skriva en sammanfattning av den utländska rapporten. Arbetet utförs i samråd med en vetenskaplig expert inom området. Den färdiga ”SBU Kommenterar” rapporten publiceras på SBUs hemsida och arbetet beräknas ta tre till fyra månader att genomföra.
Arbetet ställer krav på mycket goda kunskaper i svenska och engelska i både tal och skrift.
Övriga upplysningar om projektet lämnas av projektsamordnare Mikael Nilsson, tfn 08-412 32 59, 076-856 83 84 [email protected] eller programchef Jan Liliemark, tfn, 08-412 32 71 eller 070-517 46 51, [email protected]
Bioinformatic analysis for drug discovery programs
Presentation of the company Sprint Bioscience is a Swedish pharmaceutical company focusing on early stage drug
discovery projects directed towards cancer and diabetes targets. The company is currently
composed of 24 employees specialized in medical chemistry, protein science, cell biology,
sales and marketing. Sprint Bioscience uses fragment-based drug design approaches in
order to gain a better control and understanding on the biophysical and pharmacokinetic
properties of our molecules. Another specificity relies on our initial screening steps which
involves thermal-shift assays. Taken together, these methodologies allow us to identify hits
from our in-house fragment library and to improve their affinity and specificity towards their
targets without compromising their pharmacokinetic properties when compared with
traditional high-throughput screening approaches In-house disciplines encompass
computational chemistry, synthetic chemistry, biochemistry, structural biology and cellular
and molecular biology.
Proposal of research project
Drug discovery programs are highly dependent on the models chosen during the in vitro
discovery phase. Choosing the right cellular model, with the right target in the right context
will ultimately reflect in the clinical efficacy of the compounds tested. Similarly, when moving
into in vivo studies and clinical trials, choosing appropriate animal models with high
translational value, and designing clinical trials with the highest therapeutic relevance
possible will determine the fate of the programs.
Biomedical research and health care institutions are generating enormous amounts of
data, from fully sequenced genomes to patient data regarding genotype, gene expression,
physiological parameters, drug treatment, treatment outcome, survival etc. The convergence
of all available data can be used to build hypothesis in drug discovery projects regarding
translational relevance, linkage to disease, clinical trial design, patient stratification, etc.
As mentioned above Sprint Bioscience is focusing mainly on oncology. A bioinformatics
work-flow applied to our in-house projects would add significant value to them, in the form of
target knowledge, target validation, and translational validity. Therefore, we would like to
implement bioinformatics tools to our current and future drug discovery programs.
The candidate will, in coordination with scientists involved in the current projects,
incorporate bioinformatics methodology to support the rationale and aid design of our drug
discovery programs. More specifically, the aim is to use publically available biomedical data
to evaluate if expression levels of particular biomarkers could aid in patient stratification in
our VPS34 project.
Requirements The candidate should hold a PhD in a relevant field with hands-on experience in
bioinformatics, translational bioinformatics applied to drug discovery processes. Experience
in oncology and cancer biology is a plus but not a requirement. The project will take place for
two months after January 2017.
TEL: +46 (0)8-411 44 55 E-MAIL: [email protected] VISITING ADDRESS: NOVUM, HÄLSOVÄGEN 7, LIFT A, 8TH FLOOR POSTAL ADDRESS: NOVUM, 141 57 HUDDINGE, SWEDEN
WEB: WWW.SPRINTBIOSCIENCE.COM WWW.SPRINTBIOSCIENCE.SE OCR: SE556789755701
Development of a drug screening platform for normal cells
Presentation of the company Sprint Bioscience is a Swedish pharmaceutical company focusing on early stage drug
discovery projects directed towards cancer and diabetes targets. The company is currently
composed of 24 employees specialized in medical chemistry, protein science, cell biology,
sales and marketing. Sprint Bioscience uses fragment-based drug design approaches in
order to gain a better control and understanding on the biophysical and pharmacokinetic
properties of our molecules. Another specificity relies on our initial screening steps which
involves thermal-shift assays. Taken together, these methodologies allow us to identify hits
from our in-house fragment library and to improve their affinity and specificity towards their
targets without compromising their pharmacokinetic properties when compared with
traditional high-throughput screening approaches. In-house disciplines encompass
computational chemistry, synthetic chemistry, biochemistry, structural biology and cellular
and molecular biology.
Proposal of research project A major cause for failed clinical studies in the oncology field is the severe side effects caused
by new candidate drugs on normal tissue. In this project you will be involved in early phase
drug discovery, establishing normal cell models for toxicology screening. These models
include donor blood cells, fast proliferating epithelial cells, renal epithelial cells and
hepatocytes. With our team of highly skilled researchers you will get first-hand experience on
advanced cell culture techniques and insight into early drug discovery.
Requirements The candidate should hold a PhD in a relevant field with hands-on experience in cell
culture. Experience in establishment of primary cell assays is a plus but not a requirement.
The project will take place for two months after January 2017.
TEL: +46 (0)8-411 44 55 E-MAIL: [email protected] VISITING ADDRESS: NOVUM, HÄLSOVÄGEN 7, LIFT A, 8TH FLOOR POSTAL ADDRESS: NOVUM, 141 57 HUDDINGE, SWEDEN
WEB: WWW.SPRINTBIOSCIENCE.COM WWW.SPRINTBIOSCIENCE.SE OCR: SE556789755701
1 (2)
Datum
2016-09-14
Myndigheten för tillväxtpolitiska utvärderingar och analyser
Stockholm Östersund (säte) Utlandskontor
Box 574, 101 31 Stockholm Studentplan 3, 831 40 Östersund Brasilia New Delhi Peking Tokyo Washington DC
Besöksadress: Regeringsgatan 67, 4 tr Besöksadress: Studentplan 3
Tel: 010 447 44 00 Tel: 010 447 44 00
Fax: 010 447 44 90 Fax: 010 447 44 01
[email protected] Bank: Danske Bank
www.tillvaxtanalys.se Kontonummer: 12 810 107 041
Org. nr 202100–6164 Swift: DABASESX
IBAN: SE6712 0000 000 12 810 107 041
TA300, v3.2
, 2014-0
2-1
3
Towards a Swedish megafund for bioscience
About Growth Analysis
Growth Analysis has been instructed by the Swedish Government to analyze and
evaluate Swedish growth policy. Our overall goal is to strengthen Swedish
competitiveness and to create the conditions for more jobs and for growing
businesses throughout the country.
Growth Analysis employees are experts in growth policy in a number of different
fields. We cooperate with other authorities, and we engage external experts in order
to obtain the best possible results.
Our operations are conducted in close cooperation with the Government Offices
and other players in the public sphere. Growth Analysis is an authority under the
direction of the Ministry of Enterprise and Innovation.
Project description
Large pharmaceutical companies are no longer nurturing early-stage drug
development. Venture capitalists, too, are deserting life science startups, which
averaged them negative 1 percent returns over the last decade. The result is a
growing funding gap between basic lab research and commercial drug
development. And fewer drugs are surviving the costly gauntlet of clinical trials to
eventually reach market approval.
Resent research propose that there is an opportunity to expand the pool of capital
available for life science investment by bringing together investors who would not
normally fund biomedical research and innovation to a megafund. In exchange the
investors would get a small percentage of all royalties from successful drugs or
licensing revenues.
More specifically, such megafund would apply financial engineering concepts such
as portfolio theory and securitizing of future revenues. The sheer size of the
megafund would reduce risk by diversifying investments across many more
projects, and therefore could provide investors stronger guarantees of returns than
any smaller fund.
2 (2)
Datum
2016-09-08
The aim of this project is to summarize the current literature on how to design a
megafund for bioscience and, by the means of interviews with key stakeholders,
assess the conditions and incentives for such fund in Sweden and advice on further
steps.
Requested qualifications
The ideal candidate would have:
• A background in biomedicine research
• Experience from the start-up industry, venture capital or finance
• Experience of qualitative research methods
• Fluency in English and strong writing skills (knowledge of Swedish is an
advantage).
Project period
Flexible
Contact
Carl Wadell, PhD
Analyst and Thematic director
Swedish Agency for Growth Policy Analysis
Mobil: +46 72 232 33 67
E-post: [email protected]
